Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Abstract
In addition to the devastating symptoms of psychosis, many people with schizophrenia also suffer from cognitive impairment. These cognitive symptoms lead to marked dysfunction and can impact employability, treatment adherence, and social skills. Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. This nicotinic cholinergic-mediated inhibitory process represents a potential new target for therapeutic intervention in schizophrenia. This chapter will review evidence implicating the nicotinic cholinergic, and specifically, the alpha7 nicotinic receptor system in the pathology of schizophrenia. Impaired auditory sensory gating has been linked to the alpha7 nicotinic receptor gene on the chromosome 15q14 locus. A majority of persons with schizophrenia are heavy smokers. Although nicotine can acutely reverse diminished auditory sensory gating in people with schizophrenia, this effect is lost on a chronic basis due to receptor desensitization. The alpha7 nicotinic agonist 3-(2,4 dimethoxy)benzylidene-anabaseine (DMXBA) can also enhance auditory sensory gating in animal models. DMXBA is well tolerated in humans and a new study in persons with schizophrenia has found that DMXBA enhances both P50 auditory gating and cognition. alpha7 Nicotinic acetylcholine receptor agonists appear to be viable candidates for the treatment of cognitive disturbances in schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Translational P50 research has repeatedly linked sensory gating to cholinergic modulation, particularly α7 nicotinic acetylcholine receptor mechanisms, and to local inhibitory interneuron function within hippocampal and related cortical circuits [164,169,170,171].”
In the citing paper
“Other neurotransmitters (e.g., 40), which are also implicated in schizophrenia, also modulate visual processing.”
From Visual perception and its impairment in schizophrenia (2008) · cites this paper as [40]
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Smoking and Mental Illness: A Population-Based Prevalence Study
Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000) · JAMA · doi:10.1001/jama.284.20.2606 · Cited by 2,508
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 2×
“Following the identification of genetic markers specific to the 7 nicotinic acetylcholine receptor gene (CHRNA-7) at 15q13–14 (Chini et al., 1994), P50 auditory gating was linked to the chromosome 15q14 locus of CHRNA-7 (Freedman et al., 1997).”
InfluentialSelf-citationPrevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058 · cited 1×
“The Prototypic a7 Nicotinic Agonist, Nicotine, and Schizophrenia The frequency of tobacco smoking is elevated in people with schizophrenia in both inpatient (De Leon et al., 1995; Llerena et al., 2003) and outpatient settings (Diwan et al., 1998; Hughes et al., 1986).”
BackgroundCigarette smoking: implications for psychiatric illness
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.546 · Cited by 723
Normalization of auditory physiology by cigarette smoking in schizophrenic patients
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1856 · Cited by 679
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“Decreased 7 nicotinic receptor binding has been noted in the reticular nucleus of the thalamus (Court et al., 1999), the hippocampus (Freedman et al., 1995), and the cingulate cortex (Marutle et al., 2001).”
BackgroundSelf-citationNicotinic acetylcholine involvement in cognitive function in animals
Levin, E. D., & Simon, B. B. (1998) · Psychopharmacology · doi:10.1007/s002130050667 · Cited by 678
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1189 · Cited by 579
West, K. A., Brognard, J., Clark, A. S., Linnoila, I. R., Yang, X., Swain, S. M., Harris, C. C., Belinsky, S. A., & Dennis, P. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16147 · Cited by 576
Benowitz, N. L., & Gourlay, S. G. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00079-x · Cited by 529 · cited 1×
“…nicotine use are unknown and may include carcinogenic risk (Crowley-Weber et al., 2003; Heusch and Maneckjee, 1998) and cerebro-or cardiovascular risk (Benowitz, 2003; Benowitz and Gourlay, 1997; Chalon et al., 2000; Elliott et al., 2003; Fang et al., 2003; Hakki et al., 2002; West et al., 2003).”
BackgroundProof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Self-citationWest, K. A., Brognard, J., Clark, A. S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316147 · Cited by 503
Nicotine Dependence in Schizophrenia: Clinical Phenomena and Laboratory Findings
Dalack, G. W., Healy, D. J., & Meador-Woodruff, J. H. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1490 · Cited by 498
Freedman, R., Adler, L. E., Waldo, M. C., Pachtman, E., & Rd, F. (1983) · PubMed · Cited by 472
Self-citationNicotinic receptors in the brain: correlating physiology with function
Jones, S., Sudweeks, S., & Yakel, J. L. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01471-x · Cited by 450
Leonard, S., Gault, J., Hopkins, J., Logel, J., Vianzon, R., Short, M., Drebing, C., Berger, R., Venn, D., Sirota, P., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1085 · Cited by 441
Self-citationSchizophrenia and smoking: an epidemiological survey in a state hospital
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.3.453 · Cited by 418
Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics
Adler, L. E., Hoffer, L. J., Griffith, J., Waldo, M. C., & Freedman, R. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90073-9 · Cited by 412
Self-citationSiegel, C. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790170081009 · Cited by 382
Frazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-04-01187.1998 · Cited by 374 · cited 1×
“7 Nicotinic receptors mediate this inhibitory processing by enhancing the release of gama-aminobutyric acid (GABA) from GABAergic interneurons via a postsynaptic, calcium-dependent mechanism (Albuquerque et al., 1998; Frazier et al., 1998).”
BackgroundSelf-citationCognitive function in schizophrenia
Sharma, T., & Antonova, L. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00084-9 · Cited by 367
George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T., Satterburg, C. A., Winkel, J., Rounsaville, B. J., & Kosten, T. R. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1835 · Cited by 354
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
Martin, L., Kem, W., & Freedman, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1750-1 · Cited by 342
Self-citationNicotine-Haloperidol Interactions and Cognitive Performance in Schizophrenics
Levin, E. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00018-8 · Cited by 342
Sacco, K. A., Termine, A., Seyal, A., Dudas, M. M., Vessicchio, J. C., Krishnan-Sarin, S., Jatlow, P. I., Wexler, B. E., & George, T. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.649 · Cited by 330
Kelly, C., & McCreadie, R. G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1751 · Cited by 317
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists
Goff, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., Bierer, M., Duckworth, K., & Sacks, F. M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0205 · Cited by 311
Guan, Z.-Z., Zhang, X., Blennow, K., & Nordberg, A. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00028 · Cited by 286
Faraone, S. V., Matise, T., Svrakic, D., Pepple, J., Malaspina, D., Suarez, B., Hampe, C., Zambuto, C. T., Schmitt, K., Meyer, J., et al. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980710)81:4<290::aid-ajmg3>3.0.co;2-y · Cited by 279
Ziedonis, D. M., & George, T. P. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.2.247 · Cited by 278
Poor P50 Suppression Among Schizophrenia Patients and Their First-Degree Biological Relatives
Clementz, B. A., Geyer, M. A., & Braff, D. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.12.1691 · Cited by 276
Selective α 7 -nicotinic agonists normalize inhibition of auditory response in DBA mice
Stevens, K. E., Kem, W. R., Mahnir, V. M., & Freedman, R. (1998) · Psychopharmacology · doi:10.1007/s002130050573 · Cited by 269
Self-citationKaufmann, C. A., Suarez, B., Malaspina, D., Pepple, J., Svrakic, D., Markel, P. D., Meyer, J., Zambuto, C. T., Schmitt, K., Matise, T. C., et al. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980710)81:4<282::aid-ajmg2>3.0.co;2-w · Cited by 267
Cholinergic gating of response to auditory stimuli in rat hippocampus
Luntz-Leybman, V., Bickford, P. C., & Freedman, R. (1992) · Brain Research · doi:10.1016/0006-8993(92)91437-j · Cited by 264
Self-citationSensory gating deficits in schizophrenia: new results
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.488 · Cited by 263
Court, J., Spurden, D., Lloyd, S., McKeith, I., Ballard, C., Cairns, N., Kerwin, R., Perry, R., & Perry, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731590.x · Cited by 254
Olincy, A., Young, D. A., & Freedman, R. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00302-2 · Cited by 252
Self-citationSmith, R. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00324-x · Cited by 247
Gault, J., Robinson, M., Berger, R., Drebing, C., Logel, J., Hopkins, J., Moore, T., Jacobs, S., Meriwether, J., Choi, M. J., et al. (1998) · Genomics · doi:10.1006/geno.1998.5363 · Cited by 245
Self-citationKitagawa, H., Takenouchi, T., Azuma, R., Wesnes, K. A., Kramer, W. G., Clody, D. E., & Burnett, A. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300028 · Cited by 238
Effects of Nicotine on Cognitive Deficits in Schizophrenia
Harris, J. G., Kongs, S., Allensworth, D., Martin, L., Tregellas, J., Sullivan, B., Zerbe, G., & Freedman, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300450 · Cited by 237
Self-citationNicotine effects on brain function and functional connectivity in schizophrenia
Jacobsen, L. K., D'Souza, D. C., Mencl, W. E., Pugh, K. R., Skudlarski, P., & Krystal, J. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.023 · Cited by 232
Kem, W. R. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00211-4 · Cited by 231
Smoking Cessation Treatment for Patients With Schizophrenia
Addington, J., el-Guebaly, N., Campbell, W., Hodgins, D. C., & Addington, D. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.974 · Cited by 229
Ji, D., & Dani, J. A. (2000) · Journal of Neurophysiology · doi:10.1152/jn.2000.83.5.2682 · Cited by 227
Effects of Smoking Abstinence on Visuospatial Working Memory Function in Schizophrenia
George, T. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00296-2 · Cited by 226
Splitting Schizophrenia: Periodic Catatonia–Susceptibility Locus on Chromosome 15q15
Stöber, G., Saar, K., Rüschendorf, F., Meyer, J., Nürnberg, G., Jatzke, S., Franzek, E., Reis, A., Lesch, K.-P., Wienker, T. F., et al. (2000) · The American Journal of Human Genetics · doi:10.1016/s0002-9297(07)62950-4 · Cited by 220
Schizophrenia and Nicotinic Receptors
Freedman, R., Adler, L. E., Bickford, P., Byerley, W., Coon, H., Cullum, M. C., Griffith, J. M., Harris, J. G., Leonard, S., Miller, C., et al. (1994) · Harvard Review of Psychiatry · doi:10.3109/10673229409017136 · Cited by 217
Self-citationNeurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia
Cullum, C. M., Harris, J. G., Waldo, M. C., Smernoff, E., Madison, A., Nagamoto, H. T., Griffith, J., Adler, L. E., & Freedman, R. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90048-n · Cited by 212 · cited 1×
“This inhibitory failure is associated with poor sustained attention, as measured by diminished performance on the Digit Vigilance Test and other tests of attentional dysfunction (Cullum et al., 1993; Yee et al., 1998).”
MethodSelf-citationNormal P50 Suppression in Schizophrenia Patients Treated With Atypical Antipsychotic Medications
Light, G. A., Geyer, M. A., Clementz, B. A., Cadenhead, K. S., & Braff, D. L. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.767 · Cited by 206
Stevens, K. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00178-g · Cited by 203
Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells
Heusch, W. (1998) · Carcinogenesis · doi:10.1093/carcin/19.4.551 · Cited by 203
Shirazi-Southall, S. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00400-6 · Cited by 201
(1998) · doi:10.1093/oso/9780195114966.001.0001 · Cited by 198
Arendash, G. W., Sengstock, G. J., Sanberg, P. R., & Kem, W. R. (1995) · Brain Research · doi:10.1016/0006-8993(94)01449-r · Cited by 198
Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
Adler, L. E., Olincy, A., Cawthra, E. M., McRae, K. A., Harris, J. G., Nagamoto, H. T., Waldo, M. C., Hall, M.-H., Bowles, A., Woodward, L., et al. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1822 · Cited by 197
Self-citationde Fiebre, C. M., Meyer, E. M., Henry, J. C., Muraskin, S. I., Kem, W. R., & Papke, R. L. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08515-3 · Cited by 197
Briggs, C. A., Anderson, D. J., Brioni, J. D., Buccafusco, J. J., Buckley, M. J., Campbell, J. E., Decker, M. W., DONNELLY–ROBERTS, D., Elliott, R. L., Gopalakrishnan, M., et al. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00354-1 · Cited by 193
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110073920 · Cited by 191 · cited 5×
“Successful interventions have utilized cognitive behavioral therapy and sustained release bupropion (Evins et al., 2001; Weiner et al., 2001), nicotine replacement therapy (Breckenridge, 1990; Chou et al.”
BackgroundMethodInfluentialReplication and Extension of P50 Findings in Schizophrenia
Boutros, N. N., Zouridakis, G., & Overall, J. (1991) · Clinical Electroencephalography · doi:10.1177/155005949102200109 · Cited by 189
Jeste, S. D., Patterson, T. L., Palmer, B. W., Dolder, C. R., Goldman, S., & Jeste, D. V. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00314-6 · Cited by 184
Effects of clozapine on smoking in chronic schizophrenic outpatients.
George, T. P., Sernyak, M. J., Ziedonis, D. M., & Woods, S. W. (1995) · PubMed · Cited by 179
Development of nicotinic drug therapy for cognitive disorders
Levin, E. D., & Rezvani, A. H. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00885-7 · Cited by 176
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia
Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., Perry, E., & Nordberg, A. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00117-x · Cited by 175
Dépatie, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00372-x · Cited by 175
Smoking and therapeutic response to clozapine in patients with schizophrenia
McEvoy, J. P., Freudenreich, O., & Wilson, W. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00377-1 · Cited by 172
P50 Suppression among schizophrenia and normal comparison subjects: A methodological analysis
Clementz, B. A., Geyer, M. A., & Braff, D. L. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00208-9 · Cited by 170
Steinberg, M. L., Ziedonis, D. M., Krejci, J. A., & Brandon, T. H. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.4.723 · Cited by 169
A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus
Hunter, B. E., de Fiebre, C. M., Papke, R. L., Kem, W. R., & Meyer, E. M. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90433-2 · Cited by 160
Macor, J. E., Gurley, D., Lanthorn, T., Loch, J., Mack, R. A., Mullen, G., Tran, O., Wright, N., & Gordon, J. C. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00670-3 · Cited by 159
Crowley-Weber, C. L., Dvořáková, K., Crowley-Skillicorn, C., Bernstein, H., Bernstein, C., Garewal, H. S., & Payne, C. M. (2003) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00162-x · Cited by 158
Meyer, E. M., Tay, E. T., Papke, R. L., Meyers, C., Huang, G.-L., & de Fiebre, C. M. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00536-2 · Cited by 158
Smoking and Malignancy in Schizophrenia
Masterson, E., & O'Shea, B. (1984) · British Journal of Psychiatry · doi:10.1192/bjp.145.4.429 · Cited by 155
Ziedonis, D. M., Williams, J. M., & Smelson, D. A. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200310000-00014 · Cited by 154
Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders
Diwan, A., Castine, M., Pomerleau, C. S., Meador-Woodruff, J. H., & Dalack, G. W. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00045-0 · Cited by 152 · cited 3×
“Their motivation to quit smoking is low (Addington et al., 1997; Ziedonis and George, 1997), and the smoking cessation rate is lower than the rates of other mentally ill populations (Diwan et al., 1998) and the general population (Kelly and McCreadie, 1999).”
BackgroundNicotine Dependence, Midbrain Dopamine Systems and Psychiatric Disorders
Nisell, M., Nomikos, G. G., & Svensson, T. H. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb00123.x · Cited by 143
Improvement in Smooth Pursuit Eye Movements after Cigarette Smoking in Schizophrenic Patients
D, A. O. M. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00095-x · Cited by 136
Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature
Dalack, G. W., & Meador‐Woodruff, J. H. (1996) · Schizophrenia Research · doi:10.1016/s0920-9964(96)80441-5 · Cited by 135
Nicotine Withdrawal and Psychiatric Symptoms in Cigarette Smokers with Schizophrenia
Dalack, G. W., Becks, L., Hill, E., Pomerleau, O. F., & Meador-Woodruff, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00121-3 · Cited by 133
Meyer, E. M., Kuryatov, A., Gerzanich, V., Lindstrom, J., & Papke, R. L. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37881-4 · Cited by 131
Mullen, G., Napier, J., Balestra, M., DeCory, T., Hale, G., Macor, J., Mack, R., Loch, J., Wu, E., Kover, A., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000249r · Cited by 130
Codistribution of a sensory gating deficit and schizophrenia in multi-affected families
Waldo, M. C., Carey, G., Myles‐Worsley, M., Cawthra, E. M., Adler, L. E., Nagamoto, H. T., Wender, P. H., Byerley, W., Plaetke, R., & Freedman, R. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90092-4 · Cited by 129
Self-citationLeonard, S., Gault, J., Moore, T., Hopkins, J., Robinson, M., Olincy, A., Adler, L. E., Cloninger, C. R., Kaufmann, C. A., Tsuang, M. T., et al. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980710)81:4<308::aid-ajmg6>3.0.co;2-p · Cited by 129
Self-citationRole of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness
Nomikos, G. G., Schilström, B., Hildebrand, B. E., Panagis, G., Grenhoff, J., & Svensson, T. H. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00204-7 · Cited by 127
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
Koike, K., Hashimoto, K., Takai, N., Shimizu, E., Komatsu, N., Watanabe, H., Nakazato, M., Okamura, N., Stevens, K. E., Freedman, R., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.016 · Cited by 127
Self-citationKumari, V., Soni, W., & Sharma, T. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.286 · Cited by 126
P50 suppression in recent-onset schizophrenia: Clinical correlates and risperidone effects.
Yee, C. M., Nuechterlein, K. H., Morris, S. E., & White, P. M. (1998) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.107.4.691 · Cited by 124
Riley, B. P., Makoff, A., Mogudi-Carter, M., Jenkins, T., Williamson, R., Collier, D., & Murray, R. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000403)96:2<196::aid-ajmg15>3.0.co;2-4 · Cited by 124
Nicotine impairs endothelium‐dependent dilatation in human veins in vivo
Chalon, S., Moreno, H., Benowitz, N., Hoffman, B. B., & Blaschke, T. F. (2000) · Clinical pharmacology and therapy · doi:10.1067/mcp.2000.105153 · Cited by 121
Simosky, J. K., Stevens, K. E., Adler, L. E., & Freedman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1285-x · Cited by 121
Self-citationAdler, L. E., Waldo, M. C., & Freedman, R. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90113-1 · Cited by 120
Self-citationα7 Receptor-selective agonists and modes of α7 receptor activation
Papke, R. L., Meyer, E. M., Nutter, T., & Uteshev, V. V. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00009-1 · Cited by 120
Woodruff‐Pak, D. S., Li, Y.-T., & Kem, W. R. (1994) · Brain Research · doi:10.1016/0006-8993(94)91665-9 · Cited by 119
Kem, W. R., Mahnir, V. M., Papke, R. L., & Lingle, C. J. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37134-4 · Cited by 119
Thomson, G. W., & Wilson, N. (2004) · Tobacco Control · doi:10.1136/tc.2004.007492 · Cited by 117
The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?
Olivier, B., Leahy, C. L., Mullen, T., Paylor, R. E., Groppi, V. E., Sarnyai, Z., & Brunner, D. (2001) · Psychopharmacology · doi:10.1007/s002130100828 · Cited by 114
Readiness to Stop Smoking in Schizophrenia
Addington, J., el-Guebaly, N., Addington, D., & Hodgins, D. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200107 · Cited by 112
Schizophrenia and the Motivation for Smoking
Forchuk, C., Norman, R., Malla, A., Martin, M.-L., McLean, T., Cheng, S., Diaz, K., Mcintosh, E., Rickwood, A., Vos, S., et al. (2009) · Perspectives in Psychiatric Care · doi:10.1111/j.1744-6163.2002.tb00656.x · Cited by 110
Nicotinic receptor desensitization and sensory gating deficits in schizophrenia
Griffith, J. M., O'Neill, J. E., Petty, F., Garver, D. L., Young, D. A., & Freedman, R. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00362-4 · Cited by 110
Self-citationAlkondon, M., Braga, M. F. M., Pereira, E. F. R., Maelicke, A., & Albuquerque, E. X. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00006-6 · Cited by 108
Cigarette smoking and neuroleptic-induced parkinsonism
Decina, P., Caracci, G., Sandik, R., Berman, W., Mukherjee, S., & Scapicchio, P. L. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90483-i · Cited by 108
Nagamoto, H. T., Adler, L. E., McRae, K. A., Huettl, P., Cawthra, E., Gerhardt, G., Hea, R., & Griffith, J. (1999) · Neuropsychobiology · doi:10.1159/000026553 · Cited by 107
Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice
Simosky, J. K., Stevens, K. E., Kem, W. R., & Freedman, R. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01093-9 · Cited by 106
Self-citationBuchanan, R. W., Summerfelt, A. T., Tek, C., & Gold, J. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00387-5 · Cited by 105
Albuquerque, E. X., Pereira, E. F. R., Mike, Á., Eisenberg, H. M., Maelicke, A., & Alkondon, M. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00208-4 · Cited by 105
Weiner, E., Ball, M. P., Summerfelt, A., Gold, J., & Buchanan, R. W. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.635 · Cited by 103
Meyer, E. M., de Fiebre, C. M., Hunter, B. E., Simpkins, C. E., Frauworth, N., & de Fiebre, N. E. C. (1994) · Drug Development Research · doi:10.1002/ddr.430310207 · Cited by 103
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., & Court, J. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00348-2 · Cited by 100 · cited 2×
“Reduced 7 subunit levels have been noted in frontal lobe regions (Guan et al., 1999), including the dorsolateral prefrontal cortex (Martin-Ruiz et al., 2003).”
BackgroundKem, W. R., Mahnir, V. M., Prókai, L., Papke, R. L., Cao, X., LeFrancois, S., Wildeboer, K. M., Prókai-Tátrai, K., Porter-Papke, J., & Soti, F. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.56 · Cited by 100
Chini, B., Raimond, E., Elgoyhen, A. B., Moralli, D., Balzaretti, M., & Heinemann, S. (1994) · Genomics · doi:10.1006/geno.1994.1075 · Cited by 99
Tidey, J. W., O'Neill, S. C., & Higgins, S. T. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.10.3.241 · Cited by 98
Neurobiology of Smooth Pursuit Eye Movement Deficits in Schizophrenia: An fMRI Study
Tregellas, J. R., Tanabe, J. L., Miller, D. E., Ross, R. G., Olincy, A., & Freedman, R. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.315 · Cited by 97
Self-citationThe effects of nicotine on specific eye tracking measures in schizophrenia
Sherr, J. D., Myers, C. S., Avila, M. T., Elliott, A., Blaxton, T. A., & Thaker, G. K. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01342-2 · Cited by 95
Nicotine improves delayed recognition in schizophrenic patients
Myers, C. S., Robles, O., Kakoyannis, A. N., Sherr, J. D., Avila, M. T., Blaxton, T. A., & Thaker, G. K. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1764-8 · Cited by 95
Human α 7 nicotinic acetylcholine receptor responses to novel ligands
Briggs, C. A., McKenna, D. G., & Piattina-kaplan, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00028-5 · Cited by 94
Isolation and structure of a hoplonemertine toxin
Kem, W. R., ABBOTT, B. C., & Coates, R. M. (1971) · Toxicon · doi:10.1016/0041-0101(71)90039-0 · Cited by 93
Autistic symptoms among children and young adults with isodicentric chromosome 15
Rineer, S., Finucane, B., & Simon, E. W. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980907)81:5<428::aid-ajmg12>3.0.co;2-e · Cited by 92
Evins, A. E., Cather, C., Rigotti, N. A., Freudenreich, O., Henderson, D. C., Olm-Shipman, C. M., & Goff, D. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0304 · Cited by 88
Strand, J.-E., & Nybäck, H. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.005 · Cited by 88
Xu, J., Pato, M. T., Torre, C. D., Medeiros, H., Carvalho, C., Basile, V. S., Bauer, A., Dourado, A., Valente, J., Soares, M. J., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1549 · Cited by 85
GABAB antagonists diminish the inhibitory gating of auditory response in the rat hippocampus
Hershman, K. M., Freedman, R., & Bickford, P. C. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11523-y · Cited by 84
Self-citationSchreiber, R., Dalmus, M., & Vry, J. D. (2001) · Psychopharmacology · doi:10.1007/s00213-001-0927-8 · Cited by 84
Liu, C., Hwu, H., Lin, M., Ou‐Yang, W., Lee, S. F. ‐., Fann, C. S. J., Wong, S., & Hsieh, S. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1547 · Cited by 83
A Concordance Study of Three Electrophysiological Measures in Schizophrenia
la Chapelle, S. L.-D., Nkam, I., Houy‐Durand, E., Belmont, A., Ménard, J.-F., Roussignol, A.-C., Siwek, O., Mezerai, M., Guillermou, M., Fouldrin, G., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.466 · Cited by 83
Meyer, E. M., Tay, E. T., Zoltewicz, J. A., Meyers, C., King, M. A., Papke, R. L., & De Fiebre, C. M. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37338-0 · Cited by 83
Avila, M. T., Sherr, J. D., Hong, E. L., Myers, C. S., & Thaker, G. K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300265 · Cited by 82
Weickert, T. W., Goldberg, T. E., Marenco, S., Bigelow, L. B., Egan, M. F., & Weinberger, D. R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300216 · Cited by 82
Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients
Adler, L. E., Cawthra, E. M., Donovan, K. A., Harris, J. G., Nagamoto, H. T., Olincy, A., & Waldo, M. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.386 · Cited by 82
Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
Adler, L. E. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.10.1822 · Cited by 81
Tsuang, D. W., Skol, A. D., Faraone, S. V., Bingham, S., Young, K. A., Prabhudesai, S., Haverstock, S. L., Mena, F., Menon, A. S., Bisset, D., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1550 · Cited by 80
D, A. O. M., Johnson, L. L., & Ross, R. G. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00022-2 · Cited by 80
Albuquerque, E. X., Pereira, E. F. R., Braga, M. F. M., & Alkondon, M. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80039-9 · Cited by 77
Rosse, R. B., & Deutsch, S. I. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200209000-00010 · Cited by 74
Warburton, P., Baird, G., Chen, W., Morris, K., Jacobs, B. W., Hodgson, S., & Docherty, Z. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000403)96:2<228::aid-ajmg20>3.0.co;2-g · Cited by 72
The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia
Chou, K., Chen, R., Lee, J.-F., Ku, C., & Lu, R. (2003) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2003.07.001 · Cited by 72
Nicotine reduces antisaccade errors in task impaired schizophrenic subjects
Larrison, A. L., MATORIN, A. A., & Sereno, A. B. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.01.002 · Cited by 71
Nicotine Decreases Bradykinesia-rigidity in Haloperidol-treated Patients with Schizophrenia
Yang, Y. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00325-1 · Cited by 71
Linkage of M5 Muscarinic and α7-Nicotinic Receptor Genes on 15q13 to Schizophrenia
De Luca, V., Wang, H., Squassina, A., Wong, G. W. H., Yeomans, J., & Kennedy, J. L. (2004) · Neuropsychobiology · doi:10.1159/000079102 · Cited by 69
Houy, E., Raux, G., Thibaut, F., Belmont, A., Demily, C., Allio, G., Haouzir, S., Fouldrin, G., Petit, M., Frébourg, T., et al. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001443 · Cited by 67
No evidence for linkage between schizophrenia and markers at chromosome 15q13-14
Curtis, L., Blouin, J.-L., Radhakrishna, U., Gehrig, C., Lasseter, V. K., Wolyniec, P., Nestadt, G., Dombroski, B., Kazazian, H. H., Pulver, A. E., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990416)88:2<109::aid-ajmg1>3.0.co;2-3 · Cited by 66
Bickford, P. C., & Wear, K. D. (1995) · Brain Research · doi:10.1016/0006-8993(95)01157-9 · Cited by 63
Hashimoto, K., Iyo, M., Freedman, R., & Stevens, K. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0142-0 · Cited by 63
Self-citationNeves-Pereira, M., Bassett, A. S., Honer, W. G., Lang, D., King, N. A., & Kennedy, J. L. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980907)81:5<361::aid-ajmg3>3.0.co;2-w · Cited by 63
Smoking and cognitive deficits in schizophrenia: a pilot study
Taiminen, T. J., Salokangas, R. K. R., Saarijãrvi, S., Niemi, H., Lehto, H., Ahola, V., & Syvälahti, E. K. G. (1998) · Addictive Behaviors · doi:10.1016/s0306-4603(97)00028-2 · Cited by 61
Replication of a P50 auditory gating deficit in Australian patients with schizophrenia
Ward, P. B., Hoffer, L., Liebert, B. J., Catts, S. V., O׳Donnell, M., & Adler, L. E. (1996) · Psychiatry Research · doi:10.1016/0165-1781(96)02876-4 · Cited by 61
Hippocampal Function and Schizophrenia. Experimental Psychological Evidencea
Venables, P. H. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb22841.x · Cited by 59
Perl, O., Ilani, T., Strous, R. D., Lapidus, R., & Fuchs, S. (2003) · The FASEB Journal · doi:10.1096/fj.03-0104fje · Cited by 59
Combs, D. R., & Advokat, C. D. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00026-8 · Cited by 59
Effect of Nicotine on Dynamic Function of Brain Catecholamine Neurons
Svensson, T. H., Grenhoff, J., & Engberg, G. (2007) · Novartis Foundation Symposia · doi:10.1002/9780470513965.ch10 · Cited by 58
Schizophrenia and tobacco smoking in a Spanish psychiatric hospital
LLerena, A., DELARUBIA, A., Peñas‐Lledó, E., Díaz, F. J., & DELEON, J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00327-9 · Cited by 57
The cost of cognitive impairment in schizophrenia
Sevy, S. M., & Davidson, M. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(95)00025-h · Cited by 56
Ross, R. G., Olincy, A., Harris, J. G., Radant, A., Hawkins, M., Adler, L. E., & Freedman, R. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990416)88:2<188::aid-ajmg17>3.0.co;2-e · Cited by 56
Self-citationUse of a neurophysiological trait in linkage analysis of schizophrenia
Coon, H. H., Plaetke, R., Holik, J., Hoff, M., Myles‐Worsley, M., Waldo, M., Freedman, R., & Byerley, W. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90085-r · Cited by 55
Self-citationfMRI of Response to Nicotine During a Smooth Pursuit Eye Movement Task in Schizophrenia
Tregellas, J. R., Tanabe, J. L., Martin, L. F., & Freedman, R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.391 · Cited by 55
Self-citationSchizophrenia and tobacco smoking in a Spanish psychiatric hospital
LLerena, A., de la Rubia, A., Peñas‐Lledó, E., Díaz, F. J., & de León, J. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00508-x · Cited by 53
Papke, R. L., Schiff, H. C., Jack, B. A., & Horenstein, N. A. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.025 · Cited by 51
Financial implications of cigarette smoking among individuals with schizophrenia
Steinberg, M. L., Williams, J. M., & Ziedonis, D. M. (2004) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · Cited by 51
Woodruff‐Pak, D. S. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00039-1 · Cited by 50
St�ber, G., Hebebrand, J., Cichon, S., Br�ss, M., B�nisch, H., Lehmkuhl, G., Poustka, F., Schmidt, M., Remschmidt, H., Propping, P., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990416)88:2<158::aid-ajmg12>3.0.co;2-w · Cited by 47
Olanzapine Effects on Auditory Sensory Gating in Schizophrenia
Arango, C., Summerfelt, A. T., & Buchanan, R. W. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.2066 · Cited by 47
Fang, Q., Sun, H., & Mayhan, W. G. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00752.2002 · Cited by 47
Does clozapine decrease smoking?
de León, J., Díaz, F. J., Josiassen, R. C., Cooper, T. B., & Simpson, G. M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.031 · Cited by 44
Meyer, E. M., King, M. A., & Meyers, C. (1998) · Brain Research · doi:10.1016/s0006-8993(97)00300-4 · Cited by 43
Williams, J. M., Ziedonis, D. M., & Foulds, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.9.1064 · Cited by 40
Mastropaolo, J. P., Rosse, R. B., & Deutsch, S. I. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.12.023 · Cited by 39
Treatment of neuroleptic-induced akathisia with nicotine patches
Anfang, M. K., & Pope, H. G. (1997) · Psychopharmacology · doi:10.1007/s002130050436 · Cited by 38
Stevens, K. E., Kem, W. R., & Freedman, R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00200-0 · Cited by 36
Self-citationNicotine modulation of apoptosis in human coronary artery endothelial cells
Hakki, A., Friedman, H. P., & Pross, S. H. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00059-0 · Cited by 33
Yang, Y. K., McEvoy, J. P., Wilson, W. H., Levin, E. D., & Rose, J. E. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00208-6 · Cited by 29
Adams, C. E., Stevens, K. E., Kem, W. R., & Freedman, R. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02677-9 · Cited by 28
Self-citationNicotine counteracts midbrain dopamine cell dysfunction induced by prefrontal cortex inactivation
TUNG, C. ‐., Grenhoff, J., & Svensson, T. H. (1990) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1990.tb08868.x · Cited by 27
McEvoy, J., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Sharma, T., Zipursky, R. B., Kahn, R. S., Gur, R. E., Centorrino, F., Glick, I. D., et al. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80257-8 · Cited by 26
Basic cardiovascular research and its implications for the medicinal use of nicotine
Benowitz, N. L. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02819-x · Cited by 20
No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia
Bozikas, V. P., Niopas, I., Kafantari, A., Kanaze, F. I., Gabrieli, C., Melissidis, P., Gamvrula, K., Fokas, K., & Karavatos, A. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.08.002 · Cited by 16
Breckenridge, J. S. (1990) · Psychiatric Services · doi:10.1176/ps.41.4.454-c · Cited by 13
Effects of nicotine on heart dimensions and blood volume in male and female rats
Elliott, B. M., Faraday, M. M., & Grunberg, N. E. (2003) · Nicotine & Tobacco Research · doi:10.1080/1462220031000094114 · Cited by 10
Research works printed but not linked: 1
- Kem, 1996, Two primary GTS‐21 metabolites are potent partial agonists at alpha‐7 nicotinic receptors expressed in the Xenopus oocyte, Soc. Neurosci. Abstr., 22, 268
Cited by
Functional mapping and annotation of genetic associations with FUMA
Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017) · Nature Communications · doi:10.1038/s41467-017-01261-5 · Cited by 4,083
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120
Benowitz, N. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809890 · Cited by 1,508
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979
“Nicotine acting on α7 nAChRs may improve sensory gating, which is abnormal in schizophrenics (57).”
Background
Metadata
- Authors
- Martin, L. F., & Freedman, R.
- Affiliations
- Denver VA Medical Center (US)
- ORCID
- Freedman, Robert
- Venue
- International Review of Neurobiology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 78
- Pages
- 225-246
- ISSN
- 0074-7742 (ISSN-L)
- OpenAlex
- W97382084
- Cited by
- 213
- References
- 179
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 9 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 20 · 2012: 22
- FWCI
- 25.70
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- International review of neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- schizophrenia, alpha7 nicotinic acetylcholine receptor, auditory gating, cognitive impairment, nicotine, receptor desensitization, nicotinic agonists, attentional impairment
- MeSH terms
- Acetylcholine, Animals, Brain, Cognition Disorders, Hallucinations, Humans, Receptors, Nicotinic, Schizophrenia, Nicotinic Agonists, Genetic Predisposition to Disease, Sensory Gating, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.